Draft:Endpoints News
American news publication for pharmaceutical industry
From Wikipedia, the free encyclopedia
Endpoints News is an American digital news publication focused on the biotechnology and pharmaceutical industries. Founded in 2016 by John Carroll and Arsalan Arif, it reports on drug development, regulatory affairs, and biotech investment. In 2023, the Financial Times acquired a controlling stake in the company to expand its coverage of the biopharmaceutical industry..[1][2].
Submission declined on 25 October 2025 by TheObsidianGriffon (talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
| Submission declined on 8 July 2025 by Hoary (talk). This draft's references do not show that the subject meets Wikipedia's criteria for inclusion for organizations and companies. The draft requires multiple published secondary sources that:
Declined by Hoary 8 months ago.
| |
Comment: Where is the substantive description or discussion of Endpoints News (EN), in reliable sources independent of EN and of each other?I noticed Endpoints News' reporting has been referenced in Semafor, CNBC, The New York Times, Wall Street Journal, and NPR. I clicked on the reference for the first of these. (Tip, one has to be quick to search within the page for "Endpoints" -- before an obnoxious and irremovable pop-up takes over the screen.) No description or discussion of EN, thus no evidence for notability. If any of the other four says something worth summarizing, then summarize it; if it doesn't, then skip any mention of it. -- Hoary (talk) 02:08, 8 July 2025 (UTC)
Drew Armstrong was appointed executive editor in 2022 after serving as Bloomberg’s senior editor for health care[3].
Media Appearances
In 2023, the Financial Times acquired a majority stake in Endpoints News. Reuters[1] reported that the acquisition reflected the FT’s strategy to expand into the U.S. and biopharma markets, while Axios[4] published an interview with FT executive Matt Fottrell on the motivations for the deal. The media industry outlet A Media Operator[5] analyzed the potential implications of the acquisition for Endpoints News’ subscription model.
Endpoints News reporting has been cited by mainstream and pharmaceutical news organizations. In 2025, the outlet first reported on FDA official Vinay Prasad’s departure[6] and subsequent return[7], coverage later referenced by Reuters[8], The Guardian[9][10], and Fierce Pharma[11].
Other examples of recognition include Semafor highlighting Endpoints reporting on the pharmaceutical industry’s leadership under a potential second Trump administration[12]; CNBC crediting Endpoints with breaking news of staff cuts at health company Noom[13]; The New York Times quoting founding editor John Carroll as an industry voice during the COVID-19 pandemic in an article about Biogen's super-spreader event[14]; and a Wall Street Journal op-ed on the Inflation Reduction Act citing Endpoints’ exclusive reporting on Eli Lilly’s cancellation of a cancer treatment[15][16]
- provide significant coverage: discuss the subject in detail, excluding routine coverage like product launches, staff appointments, or financial reports and listings in databases or listicles;
- are reliable: from reputable outlets with editorial oversight;
- are independent: not connected to the subject, such as press releases, the subject's own website, or sponsored content.
Please add references that meet all three of these criteria. If none exist, the subject is not yet suitable for Wikipedia.